{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:08:00Z","timestamp":1791176880990,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T00:00:00Z","timestamp":1408752000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2458-14-867","type":"journal-article","created":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T01:01:14Z","timestamp":1408755674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["HPV catch-up vaccination of young women: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Elisabeth","family":"Couto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvil","family":"S\u00e6terdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Kristine","family":"Juvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Klemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,23]]},"reference":[{"issue":"7","key":"7005_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","volume":"7","author":"S de Sanjose","year":"2007","unstructured":"de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007, 7 (7): 453-459. 10.1016\/S1473-3099(07)70158-5.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7005_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/aje\/kwf180","volume":"157","author":"RL Winer","year":"2003","unstructured":"Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003, 157 (3): 218-226. 10.1093\/aje\/kwf180.","journal-title":"Am J Epidemiol"},{"key":"7005_CR3","first-page":"1","volume":"90","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2007","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans \/ World Health Organization. Int Agency Res Cancer. 2007, 90: 1-636.","journal-title":"Int Agency Res Cancer"},{"issue":"Pt B","key":"7005_CR4","first-page":"1","volume":"100","author":"V Bouvard","year":"2012","unstructured":"Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group: Biological agents. volume 100 B. a review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012, 100 (Pt B): 1-441.","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"issue":"1","key":"7005_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19. 10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.","journal-title":"J Pathol"},{"issue":"Suppl 3","key":"7005_CR6","first-page":"C1","volume":"25","author":"X Castellsagu\u00e9","year":"2007","unstructured":"Castellsagu\u00e9 X, de Sanjos\u00e9 S, Aguado T, Louie KS, Bruni L, Mu\u00f1oz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX: HPV and cervical cancer in the 2007 report. Vaccine. 2007, 25 (Suppl 3): C1-C230.","journal-title":"Vaccine"},{"issue":"12","key":"7005_CR7","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/ijc.21731","volume":"118","author":"DM Parkin","year":"2006","unstructured":"Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006, 118 (12): 3030-3044. 10.1002\/ijc.21731.","journal-title":"Int J Cancer"},{"issue":"4","key":"7005_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","volume":"10","author":"V Bouvard","year":"2009","unstructured":"Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009, 10 (4): 321-322. 10.1016\/S1470-2045(09)70096-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7005_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1071\/SH08079","volume":"6","author":"JM Brotherton","year":"2009","unstructured":"Brotherton JM, Heywood A, Heley S: The incidence of genital warts in Australian women prior to the national vaccination program. Sex Health. 2009, 6 (3): 178-184. 10.1071\/SH08079. doi: 110.1071\/SH08079","journal-title":"Sex Health"},{"issue":"Suppl 3","key":"7005_CR10","first-page":"S3\/35","volume":"24","author":"CJ Lacey","year":"2006","unstructured":"Lacey CJ, Lowndes CM, Shah KV: Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease. Vaccine. 2006, 24 (Suppl 3): S3\/35-S33\/41.","journal-title":"Vaccine"},{"key":"7005_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2407-12-30","volume":"12","author":"S Hartwig","year":"2012","unstructured":"Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsague X: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer. 2012, 12: 30-10.1186\/1471-2407-12-30.","journal-title":"BMC Cancer"},{"issue":"2","key":"7005_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.vaccine.2007.10.057","volume":"26","author":"JM Brotherton","year":"2008","unstructured":"Brotherton JM: How much cervical cancer in Australia is vaccine preventable? a meta-analysis. Vaccine. 2008, 26 (2): 250-256. 10.1016\/j.vaccine.2007.10.057. Epub 2007 Nov 2020","journal-title":"Vaccine"},{"key":"7005_CR13","unstructured":"Plotkin S, Orenstein O, Offit P: Vaccines. 2013, Elsevier, ISBN: 978-1-4557-0090-5"},{"issue":"Suppl 5","key":"7005_CR14","doi-asserted-by":"publisher","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","volume":"30","author":"LE Markowitz","year":"2012","unstructured":"Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM: Human papillomavirus vaccine introduction--the first five years. Vaccine. 2012, 30 (Suppl 5): F139-F148. doi:110.1016\/j.vaccine.2012.1005.1039","journal-title":"Vaccine"},{"issue":"50","key":"7005_CR15","doi-asserted-by":"publisher","first-page":"8352","DOI":"10.1016\/j.vaccine.2007.09.027","volume":"25","author":"G La Torre","year":"2007","unstructured":"La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W: HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine. 2007, 25 (50): 8352-8358. 10.1016\/j.vaccine.2007.09.027. Epub 2007 Sep 8329","journal-title":"Vaccine"},{"issue":"5","key":"7005_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1503\/cmaj.070948","volume":"177","author":"L Rambout","year":"2007","unstructured":"Rambout L, Hopkins L, Hutton B, Fergusson D: Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007, 177 (5): 469-479. 10.1503\/cmaj.070948.","journal-title":"CMAJ"},{"key":"7005_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2334-11-13","volume":"11","author":"B Lu","year":"2011","unstructured":"Lu B, Kumar A, Castellsague X, Giuliano AR: Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011, 11: 13-10.1186\/1471-2334-11-13. 2011. Article Number","journal-title":"BMC Infect Dis"},{"key":"7005_CR18","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Edited by: Higgins JPT, Green S. 2011, The Cochrane Collaboration, Available from http:\/\/handbook.cochrane.org\/"},{"issue":"7650","key":"7005_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336 (7650): 924-926. 10.1136\/bmj.39489.470347.AD. doi:910.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"1","key":"7005_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","volume":"107","author":"C Mao","year":"2006","unstructured":"Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006, 107 (1): 18-27. 10.1097\/01.AOG.0000192397.41191.fb.","journal-title":"Obstet Gynecol"},{"issue":"21","key":"7005_CR21","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa020586","volume":"347","author":"LA Koutsky","year":"2002","unstructured":"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Med. 2002, 347 (21): 1645-1651. 10.1056\/NEJMoa020586.","journal-title":"New Engl J Med"},{"issue":"41","key":"7005_CR22","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","volume":"27","author":"A Rowhani-Rahbar","year":"2009","unstructured":"Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, Weiss NS, Koutsky LA: Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009, 27 (41): 5612-5619. 10.1016\/j.vaccine.2009.07.027.","journal-title":"Vaccine"},{"issue":"9576","key":"7005_CR23","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","author":"KA Ault","year":"2007","unstructured":"Ault KA: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007, 369 (9576): 1861-1868. 10.1016\/S0140-6736(07)60852-6.","journal-title":"Lancet"},{"issue":"11","key":"7005_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"LL Villa","year":"2006","unstructured":"Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen O-E, Olsson S-E, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006, 95 (11): 1459-1466. 10.1038\/sj.bjc.6603469.","journal-title":"Br J Cancer"},{"issue":"5","key":"7005_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Munoz","year":"2010","unstructured":"Munoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al: Impact of Human Papillomavirus (HPV)-6\/11\/16\/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. J Nat Cancer Inst. 2010, 102 (5): 325-339. 10.1093\/jnci\/djp534.","journal-title":"J Nat Cancer Inst"},{"issue":"10","key":"7005_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","volume":"2","author":"SK Kjaer","year":"2009","unstructured":"Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Eng HT, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Mu\u00f1oz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res. 2009, 2 (10): 868-878. 10.1158\/1940-6207.CAPR-09-0031.","journal-title":"Cancer Prev Res"},{"issue":"7766","key":"7005_CR27","first-page":"239","volume":"341","author":"J Dillner","year":"2010","unstructured":"Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garc\u00eda P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Mu\u00f1oz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT: Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ (Online). 2010, 341 (7766): 239-","journal-title":"BMJ (Online)"},{"issue":"19","key":"7005_CR28","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo\/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med. 2007, 356 (19): 1928-1943. 10.1056\/NEJMoa061760.","journal-title":"New Engl J Med"},{"issue":"1","key":"7005_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.2011.185","volume":"105","author":"X Castellsague","year":"2011","unstructured":"Castellsague X, Mu\u00f1oz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A: End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011, 105 (1): 28-37. 10.1038\/bjc.2011.185.","journal-title":"Br J Cancer"},{"issue":"9679","key":"7005_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","volume":"373","author":"N Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009, 373 (9679): 1949-1957. 10.1016\/S0140-6736(09)60691-7.","journal-title":"Lancet"},{"issue":"9580","key":"7005_CR31","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA study group: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007, 369 (9580): 2161-2170. 10.1016\/S0140-6736(07)60946-5.","journal-title":"Lancet"},{"issue":"1","key":"7005_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","volume":"13","author":"M Lehtinen","year":"2012","unstructured":"Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagu\u00e9 X, Skinner SR, Apter D, Naud P, Salmer\u00f3n J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group: Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13 (1): 89-99. 10.1016\/S1470-2045(11)70286-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7005_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow S-N, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, HPV PATRICIA Study Group: Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13 (1): 100-110. 10.1016\/S1470-2045(11)70287-X.","journal-title":"Lancet Oncol"},{"issue":"9447","key":"7005_CR34","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","volume":"364","author":"DM Harper","year":"2004","unstructured":"Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004, 364 (9447): 1757-1765. 10.1016\/S0140-6736(04)17398-4.","journal-title":"Lancet"},{"issue":"4","key":"7005_CR35","first-page":"285","volume":"55","author":"\u115f","year":"2006","unstructured":"\u115f: HPV vaccine prevents CIN. J Fam Pract. 2006, 55 (4): 285-","journal-title":"J Fam Pract"},{"issue":"9706","key":"7005_CR36","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","volume":"374","author":"The GlaxoSmithKline Vaccine HPV-007 Study Group","year":"2009","unstructured":"The GlaxoSmithKline Vaccine HPV-007 Study Group: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 64 years. The Lancet. 2009, 374 (9706): 1975-1985.","journal-title":"The Lancet"},{"issue":"38","key":"7005_CR37","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","volume":"28","author":"CN De","year":"2010","unstructured":"De CN, Teixeira J, Roteli-Martins CM, Naud P, De BP, Zahaf T, Sanchez N, Schuind A: Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine. 2010, 28 (38): 6247-6255. 10.1016\/j.vaccine.2010.07.007.","journal-title":"Vaccine"},{"issue":"3","key":"7005_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4161\/hv.18865","volume":"8","author":"CM Roteli-Martins","year":"2012","unstructured":"Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D: Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up. Hum Vaccine Immunotherapeutics. 2012, 8 (3): 390-397. 10.4161\/hv.18865.","journal-title":"Hum Vaccine Immunotherapeutics"},{"issue":"5","key":"7005_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"LL Villa","year":"2005","unstructured":"Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005, 6 (5): 271-278. 10.1016\/S1470-2045(05)70101-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7005_CR40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/ijc.26362","volume":"131","author":"A Szarewski","year":"2012","unstructured":"Szarewski A, Poppe WAJ, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagu\u00e9 X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group: Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16\/18. Int J Cancer. 2012, 131 (1): 106-116. 10.1002\/ijc.26362.","journal-title":"Int J Cancer"},{"issue":"5","key":"7005_CR41","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/j.1525-1438.2007.01123.x","volume":"18","author":"S Kang","year":"2008","unstructured":"Kang S, Kim KH, Kim YT, Kim JH, Song YS, Shin SH, Ryu HS, Han JW, Kang JH, Park SY: Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer. 2008, 18 (5): 1013-1019. 10.1111\/j.1525-1438.2007.01123.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"7005_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/cas.12106","volume":"104","author":"H Yoshikawa","year":"2013","unstructured":"Yoshikawa H, Ebihara K, Tanaka Y, Noda K: Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013, 104 (4): 465-472. 10.1111\/cas.12106.","journal-title":"Cancer Sci"},{"issue":"9","key":"7005_CR43","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1128\/CVI.00539-10","volume":"18","author":"G Leroux-Roels","year":"2011","unstructured":"Leroux-Roels G, Haelterman E, Maes C, Levy J, De BF, Licini L, David M-P, Dobbelaere K, Descamps D: Randomized trial of the immunogenicity and safety of the hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16\/18 AS04-adjuvanted cervical cancer vaccine. Clin Vaccine Immunol. 2011, 18 (9): 1510-1518. 10.1128\/CVI.00539-10.","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"7005_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4161\/hv.5.10.9518","volume":"5","author":"MH Einstein","year":"2009","unstructured":"Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G, HPV-010 Study Group: Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009, 5 (10): 705-719. 10.4161\/hv.5.10.9518.","journal-title":"Hum Vaccin"},{"issue":"3","key":"7005_CR45","first-page":"171","volume":"16","author":"HY Ngan","year":"2010","unstructured":"Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, Descamps D, Bock HL: Human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J. 2010, 16 (3): 171-179.","journal-title":"Hong Kong Med J"},{"key":"7005_CR46","volume-title":"Preventive Human Papillomavirus (HPV) Vaccines- regulatory briefing document on endpoints vaccines and related biological products advisory committee meeting November 28 and 29, 2001","author":"KL Goldenthal","year":"2001","unstructured":"Goldenthal KL, Pratt DR: Preventive Human Papillomavirus (HPV) Vaccines- regulatory briefing document on endpoints vaccines and related biological products advisory committee meeting November 28 and 29, 2001. 2001, http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/briefing\/3805b1_01.htm (accessed 2013 june 14)"},{"issue":"3","key":"7005_CR47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/91.3.252","volume":"91","author":"P Holowaty","year":"1999","unstructured":"Holowaty P, Miller AB, Rohan T, To T: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999, 91 (3): 252-258. 10.1093\/jnci\/91.3.252.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"7005_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","volume":"89","author":"GM Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Aguado T, Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003, 89 (1): 101-105. 10.1038\/sj.bjc.6601024.","journal-title":"Br J Cancer"},{"issue":"11","key":"7005_CR49","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/infdis\/jis590","volume":"206","author":"SN Tabrizi","year":"2012","unstructured":"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM: Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012, 206 (11): 1645-1651. 10.1093\/infdis\/jis590. doi: 1610.1093\/infdis\/jis1590. Epub 2012 Oct 1619","journal-title":"J Infect Dis"},{"issue":"11","key":"7005_CR50","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1038\/bjc.2014.198","volume":"110","author":"K Kavanagh","year":"2014","unstructured":"Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M: Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16\/18 and closely related HPV types. Br J Cancer. 2014, 110 (11): 2804-2811. 10.1038\/bjc.2014.198. doi:2810.1038\/bjc.2014.2198. Epub 2014 Apr 2815","journal-title":"Br J Cancer"},{"issue":"8","key":"7005_CR51","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1158\/1055-9965.EPI-13-0272","volume":"22","author":"LM Niccolai","year":"2013","unstructured":"Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE: Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev. 2013, 22 (8): 1446-1450. 10.1158\/1055-9965.EPI-13-0272. doi:1410.1158\/1055-9965.EPI-1413-0272. Epub 2013 May 1423","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"7005_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2217\/fmb.11.161","volume":"7","author":"JM Brotherton","year":"2012","unstructured":"Brotherton JM, Tabrizi SN, Garland SM: Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiol. 2012, 7 (2): 193-199. 10.2217\/fmb.11.161. doi:110.2217\/fmb.2211.2161","journal-title":"Future Microbiol"},{"issue":"12","key":"7005_CR53","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/ijc.27971","volume":"132","author":"MM Rana","year":"2013","unstructured":"Rana MM, Al E: Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer. 2013, 132 (12): 2833-2838. 10.1002\/ijc.27971.","journal-title":"Int J Cancer"},{"issue":"3","key":"7005_CR54","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/01.AOG.0000115510.81613.f0","volume":"103","author":"VB Benard","year":"2004","unstructured":"Benard VB, Eheman CR, Lawson HW, Blackman DK, Anderson C, Helsel W, Thames SF, Lee NC: Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001. Obstet Gynecol. 2004, 103 (3): 564-571. 10.1097\/01.AOG.0000115510.81613.f0.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"7005_CR55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jms.9.2.86","volume":"9","author":"JF Nygard","year":"2002","unstructured":"Nygard JF, Skare GB, Thoresen SO: The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen. 2002, 9 (2): 86-91. 10.1136\/jms.9.2.86.","journal-title":"J Med Screen"},{"issue":"3","key":"7005_CR56","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1055-9965.EPI-04-0569","volume":"14","author":"F Bray","year":"2005","unstructured":"Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, Hakama M, Parkin DM: Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005, 14 (3): 677-686. 10.1158\/1055-9965.EPI-04-0569.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 3","key":"7005_CR57","first-page":"S3\/171","volume":"24","author":"EL Franco","year":"2006","unstructured":"Franco EL, Cuzick J, Hildesheim A, De Sanjose S: Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006, 24 (Suppl 3): S3\/171-177. Epub 2006 Jun 2008","journal-title":"Vaccine"},{"issue":"9447","key":"7005_CR58","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(04)17410-2","volume":"364","author":"M Lehtinen","year":"2004","unstructured":"Lehtinen M, Paavonen J: Vaccination against human papillomaviruses shows great promise. Lancet. 2004, 364 (9447): 1731-1732. 10.1016\/S0140-6736(04)17410-2.","journal-title":"Lancet"},{"issue":"4","key":"7005_CR59","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/aje\/kwt018","volume":"178","author":"JE Tota","year":"2013","unstructured":"Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, Coutlee F, Villa LL, Franco EL: Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013, 178 (4): 625-634. 10.1093\/aje\/kwt018. doi:610.1093\/aje\/kwt1018. Epub 2013 May 1099","journal-title":"Am J Epidemiol"},{"issue":"12","key":"7005_CR60","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1002\/ijc.27586","volume":"131","author":"J Palmroth","year":"2012","unstructured":"Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, Dubin G, Lehtinen M: Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Canc J Int Canc. 2012, 131 (12): 2832-2838. 10.1002\/ijc.27586.","journal-title":"Int J Canc J Int Canc"},{"issue":"48","key":"7005_CR61","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1016\/j.vaccine.2007.09.035","volume":"25","author":"SL Kulasingam","year":"2007","unstructured":"Kulasingam SL, Pagliusi S, Myers E: Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine. 2007, 25 (48): 8110-8113. 10.1016\/j.vaccine.2007.09.035. Epub 2007 Oct 8114","journal-title":"Vaccine"},{"issue":"1","key":"7005_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4278\/ajhp.09113-ARB-364","volume":"26","author":"E Panagopoulou","year":"2011","unstructured":"Panagopoulou E, Giata O, Montgomery A, Dinas K, Benos A: Human papillomavirus and cervical screening: misconceptions undermine adherence. Am J Health Promot. 2011, 26 (1): 6-9. 10.4278\/ajhp.09113-ARB-364. doi:10.4278\/ajhp.09113-ARB-09364","journal-title":"Am J Health Promot"},{"issue":"4","key":"7005_CR63","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/pubmed\/fds040","volume":"34","author":"BF de Blasio","year":"2012","unstructured":"de Blasio BF, Neilson AR, Klemp M, Skjeldestad FE: Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era. J Public Health (Oxf). 2012, 34 (4): 539-547. 10.1093\/pubmed\/fds040.","journal-title":"J Public Health (Oxf)"},{"issue":"Suppl 3","key":"7005_CR64","first-page":"S3\/251","volume":"24","author":"TC Wright","year":"2006","unstructured":"Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A: Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine. 2006, 24 (Suppl 3): S3\/251-261.","journal-title":"Vaccine"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-14-867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-14-867\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-14-867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-14-867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T05:44:24Z","timestamp":1630561464000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-14-867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,23]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["7005"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-14-867","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,23]]},"assertion":[{"value":"24 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"867"}}